Microba reports strong growth, improved financials in FY25

Microba Life Sciences Limited (ASX:MAP) announced a robust performance for the financial year ended June 30, 2025, with revenue climbing 30% year-on-year to $15.7 million. This growth was driven by the strong adoption of its core diagnostic products, MetaXplore™ and MetaPanel™, across Australian and UK markets. The company also reported a 36% increase in cash receipts, reaching $17.0 million. Net loss after tax significantly improved to ($14,939,471) from ($19,938,485) in FY24, reflecting higher revenue, gross profit, and reduced R&D expenditure.

Microba's strong cash position was further bolstered by a $14.5 million capital raise, with $8.45 million received post-June 2025, and an expected AUD3 million from the FY25 R&D Tax Incentive in H1 FY26. The company also confirmed the re-election of Ms. Jacqueline Fernley and Dr. Hyungtae Kim as directors and is seeking shareholder approval for an additional 10% placement facility under ASX Listing Rule 7.1A, alongside the renewal of its Employee Incentive Plan.

The Annual General Meeting is scheduled for November 19, 2025, in Brisbane. Shareholders are encouraged to review the Annual Report and proxy information to participate in key resolutions, including the adoption of the Remuneration Report and equity-related proposals aimed at supporting the company’s continued growth in microbiome diagnostics and therapeutics.